Highlights in non-Hodgkin lymphoma from the Society of Hematologic Oncology (SOHO) 2023 annual meeting, including studies on chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies, and mosunetuzumab retreatment, are discussed by Dr Nastoupil of MD Anderson Cancer Center.
First, Dr Nastoupil discusses the phase 2 TRANSCEND FL study, which she presented at the conference. The study explored the CAR-T therapy lisocabtagene maraleucel (liso-cel) for relapsed/refractory follicular lymphoma. The results, she anticipates, will probably lead to US Food and Drug Administration (FDA) approval of liso-cel for this indication.
She then examines early data on mosunetuzumab and retreatment, which suggested that patients whose disease recurs can be successfully rechallenged with this CD20/CD3 bispecific antibody without any new safety signal.
Next, Dr Nastoupil looks at updates on a phase 2 study that combined CD20/CD3 bispecific antibodies with lenalidomide and rituximab. The objective response rate was high, but she commented that longer follow-up is needed.
She then discusses a study showing a durable response with epcoritamab in large cell lymphoma after longer follow-up.
Finally, Dr Nastoupil reviews a study on liso-cel in relapsed/refractory mantle cell lymphoma that resulted in very high response rates. The research may yield an FDA approval of liso-cel for mantle cell lymphoma.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Non-Hodgkin Lymphoma Highlights From SOHO 2023 - Medscape - Sep 27, 2023.
Comments